Table 2

Measures of clinical outcomes after the therapeutic intervention

Control group	Outcome	Studies, n	WMD	95% CI	p Value
High-dose nesiritide
Placebo	SVR (dynes/s/cm⁻⁵)	2	−305.17	−493.96 to −116.38	0.002
	SBP (mm Hg)	2	−6.87	−11.01 to −2.73	0.001
Dobutamine	DBP (mm Hg)	1	−6.3	−12.39 to −0.21	0.04
	SBP (mm Hg)	1	−6.3	−12.39 to −0.21	0.04
Low-dose nesiritide
Placebo	PCWP (mm Hg)	3	−4.35	−4.35 to −3.33	<0.00 001
	SVR (dynes/s/cm⁻⁵)	3	−95.35	−178.09 to −12.06	0.02
	RAP (mm Hg)	3	−5.6	−8.99 to −2.21	0.001
	SCr (mg/dL)	1	−0.02	−0.11 to 0.07	0.66
	BUN (mg/dL)	1	−2.9	−8.85 to 3.05	0.34
Dobutamine	DBP (mm Hg)	2	−2.21	−3.43 to −0.98	0.0004
Nitroglycerin	PCWP (mm Hg)	2	−2.21	−3.43 to −0.98	0.0004
	RAP (mm Hg)	1	−2.2	−3.45 to−0.95	0.0005
	SBP (mm Hg)	1	−3.9	−6.92 to −0.88	0.01
	SCr (mg/dL)	2	−0.04	−0.17 to 0.08	0.49
	CrCl (mL/min)	2	−0.82	−6.95 to 5.31	0.79

BUN, blood urea nitrogen; CrCl, creatinine clearance; DBP, diastolic blood pressure; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; SBP, systolic blood pressure; SCr, serum creatinine; SVR, systemic vascular resistance; WMD, weighted mean difference.